LEADER 01901oam  2200433I  450 
001 9910707975303321
005 20170124121941.0
035   $a(CKB)5470000002468813
035   $a(OCoLC)969906160
035   $a(EXLCZ)995470000002468813
100   $a20170124j201612    ua             0
101 0 $aeng
135   $aur|||||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aConsolidated guidance about materials licenses $eprogram-specific guidance about commercial radiopharmacy licenses, draft report for comment /$fprepared by R. L Elliot [and five others]
205   $aRev. 2.
210  1$aWashington, DC. :$cUnited States Nuclear Regulatory Commission, Office of Nuclear Material Safety and Safeguards,$dDecember 2016.
215   $a1 online resource (various pagings) $cillustrations
300   $a"NUREG-1556, volume 13, Rev. 2."
300   $a"Manuscript completed: December 2016; date published: December 2016."
300   $a"Performing organization: Division of Material Safety, State, Tribal, and Rulemaking Programs, Office of Nuclear Material Safety and Safeguards, U.S. Nuclear Regulatory Commission"--Bibliographic data sheet.
517   $aConsolidated guidance about materials licenses 
606   $aRadiopharmaceuticals$zUnited States
606   $aRadioisotopes in pharmacology$zUnited States
606   $aNuclear industry$xLicenses$zUnited States
615  0$aRadiopharmaceuticals
615  0$aRadioisotopes in pharmacology
615  0$aNuclear industry$xLicenses
700   $aElliot$b R. L.$01389626
712 02$aU.S. Nuclear Regulatory Commission.$bOffice of Nuclear Material Safety and Safeguards,
801  0$bGPO
801  1$bGPO
801  2$bGPO
906   $aBOOK
912   $a9910707975303321
996   $aConsolidated guidance about materials licenses$93441449
997   $aUNINA